phosphorus has been researched along with 8-epi-prostaglandin f2alpha in 1 studies
| Studies (phosphorus) | Trials (phosphorus) | Recent Studies (post-2010) (phosphorus) | Studies (8-epi-prostaglandin f2alpha) | Trials (8-epi-prostaglandin f2alpha) | Recent Studies (post-2010) (8-epi-prostaglandin f2alpha) |
|---|---|---|---|---|---|
| 48,074 | 1,126 | 17,139 | 1,863 | 248 | 723 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, W; Goodman, S; Grosjean, F; Post, J; Pyzik, R; Striker, GE; Uribarri, J; Vlassara, H; Woodward, M | 1 |
1 trial(s) available for phosphorus and 8-epi-prostaglandin f2alpha
| Article | Year |
|---|---|
Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease.
Topics: Aged; Biomarkers; Calcium; Calcium Carbonate; Chelating Agents; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Glycated Hemoglobin; Glycation End Products, Advanced; Humans; Inflammation; Inflammation Mediators; Kidney; Leukocytes; Lipids; Male; Middle Aged; New York City; Oxidative Stress; Phosphorus; Polyamines; Sevelamer; Severity of Illness Index; Time Factors; Treatment Outcome | 2012 |